Drugs / PF-06459988
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02297425 | Jan 2015 → Mar 2018 | — | Pfizer | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06459988 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02297425 ↗ |
| Action | Inhibit | “Epidermal Growth Factor Receptor T790m Inhibitor” NCT02297425 ↗ |
| Modality | Small molecule | — CHEMBL3786098 ↗ |
| Route | Oral | “PF-06459988 PO (tablets) continuous daily dosing” NCT02297425 ↗ |
| Target | EGFR | “PF-06459988 (Epidermal Growth Factor Receptor T790m Inhibitor)” NCT02297425 ↗ |